Curriculum - TARGET Center
... The purpose of this curriculum is to provide physicians with the information they need to educate their clinic staff and other stakeholders about integrating medication-assisted treatment (MAT) with buprenorphine into HIV primary care. It provides a detailed overview of buprenorphine within clinical ...
... The purpose of this curriculum is to provide physicians with the information they need to educate their clinic staff and other stakeholders about integrating medication-assisted treatment (MAT) with buprenorphine into HIV primary care. It provides a detailed overview of buprenorphine within clinical ...
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET REVIEW
... Clinical and epidemiological features of cases enrolled All selected studies were reviewed to extract the following data regarding the clinical and epidemiological features of cases enrolled: 1) the drugs tested to define XDR-TB cases; 2) the features of the cohort, including the number of MDR and X ...
... Clinical and epidemiological features of cases enrolled All selected studies were reviewed to extract the following data regarding the clinical and epidemiological features of cases enrolled: 1) the drugs tested to define XDR-TB cases; 2) the features of the cohort, including the number of MDR and X ...
consensus statement - Academy of Medicine of Malaysia
... Topical salicylic acid is the most frequently used keratolytic agent. It may be used alone or in conjunction with other forms of therapy. The concentration range is between 2% and 10%. Caution is to be exercised when this agent is applied extensively to body, particularly in children, since use may ...
... Topical salicylic acid is the most frequently used keratolytic agent. It may be used alone or in conjunction with other forms of therapy. The concentration range is between 2% and 10%. Caution is to be exercised when this agent is applied extensively to body, particularly in children, since use may ...
(PSD) November 2015 PBAC Meeting
... may also be considered clinical comparators; but argued that their usage was expected to be low due to the low quality of evidence, the unfavourable safety profile of dapsone, and the slow onset of action of hydroxychloroquine. There were few comparable outcomes and a number of exchangeability issue ...
... may also be considered clinical comparators; but argued that their usage was expected to be low due to the low quality of evidence, the unfavourable safety profile of dapsone, and the slow onset of action of hydroxychloroquine. There were few comparable outcomes and a number of exchangeability issue ...
Watchful Dosing of Morphine or Morphine
... Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the ...
... Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the ...
G UIDELINE Acne Guideline 2005 Update
... production is dihydrotestosterone, converted from testosterone in the sebaceous glands by the enzyme 5-alpha-reductase.8-10 The primary lesion in acne is the microcomedo. It is not visible to the naked eye but histological analysis shows hyperkeratosis of the intrafollicular sebaceous ducts and dila ...
... production is dihydrotestosterone, converted from testosterone in the sebaceous glands by the enzyme 5-alpha-reductase.8-10 The primary lesion in acne is the microcomedo. It is not visible to the naked eye but histological analysis shows hyperkeratosis of the intrafollicular sebaceous ducts and dila ...
DISCLAIMER STATEMENT
... Drugs Advisory Committee (AIDAC) can provide additional input. There have been several public discussions of the design of clinical trials and efficacy endpoints for CABP. A workshop co-sponsored by the FDA and the Infectious Diseases Society of America (IDSA) in January 2008 and several meetings of ...
... Drugs Advisory Committee (AIDAC) can provide additional input. There have been several public discussions of the design of clinical trials and efficacy endpoints for CABP. A workshop co-sponsored by the FDA and the Infectious Diseases Society of America (IDSA) in January 2008 and several meetings of ...
Viability of Customized, Marked Syringes for Gentamicin
... technically and financially feasible. However, the following needs to be considered: ...
... technically and financially feasible. However, the following needs to be considered: ...
Module 2: The Science of Addiction
... • Clinical experience has suggest that induction procedures with patients receiving long-acting opioids (e.g. methadone-maintenance patients) are basically the same as those used with patients taking shortacting opioids, except: – The time interval between the last dose of medication and the first d ...
... • Clinical experience has suggest that induction procedures with patients receiving long-acting opioids (e.g. methadone-maintenance patients) are basically the same as those used with patients taking shortacting opioids, except: – The time interval between the last dose of medication and the first d ...
Clinical Guidelines and Procedures for the Use of Naltrexone in the
... Patients should generally be encouraged to continue on their naltrexone management program for at least 6 months. ...
... Patients should generally be encouraged to continue on their naltrexone management program for at least 6 months. ...
Opioid Addiction Treatment Pharmacotherapy
... • Variation of methadone binding to plasma proteins, such as those produced by marked changes in α1-acid glycoprotein levels, might significantly alter methadone pharmacokinetics. • Within each individual, there is a genetic polymorphism of α1-acid glycoprotein • However, the pharmacological consequ ...
... • Variation of methadone binding to plasma proteins, such as those produced by marked changes in α1-acid glycoprotein levels, might significantly alter methadone pharmacokinetics. • Within each individual, there is a genetic polymorphism of α1-acid glycoprotein • However, the pharmacological consequ ...
WHO recommendations for the prevention and treatment of
... The intrinsic contribution of each component of the ‘active management of the third stage of labour’ was examined in light of new available evidence, and relevant recommendations were made. All women giving birth should be offered uterotonics during the third stage of labour for the prevention of PP ...
... The intrinsic contribution of each component of the ‘active management of the third stage of labour’ was examined in light of new available evidence, and relevant recommendations were made. All women giving birth should be offered uterotonics during the third stage of labour for the prevention of PP ...
March 2015 - Positive Recommendations
... The PBAC advised the Minister: • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS, • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more ...
... The PBAC advised the Minister: • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS, • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more ...
Per protocol analysis of therapeutic efficacy of chloroquine for the
... Background: High incidence of chloroquine-resistant vivax malaria has led to increasing case fatality and incidence of complicated malaria with Plasmodium vivax contributing to morbidity and mortality. Current guidelines recommend the use of chloroquine along with tissue schizontcides like primaquin ...
... Background: High incidence of chloroquine-resistant vivax malaria has led to increasing case fatality and incidence of complicated malaria with Plasmodium vivax contributing to morbidity and mortality. Current guidelines recommend the use of chloroquine along with tissue schizontcides like primaquin ...
Is there an interaction between erythromycin and statins?
... Atorvastatin and erythromycin should be used together with caution. It may be prudent to withhold atorvastatin if erythromycin treatment is required to avoid any potential adverse effects [4, 13, 15, 16]. If concurrent administration is unavoidable, then a lower dose of atorvastatin should be consid ...
... Atorvastatin and erythromycin should be used together with caution. It may be prudent to withhold atorvastatin if erythromycin treatment is required to avoid any potential adverse effects [4, 13, 15, 16]. If concurrent administration is unavoidable, then a lower dose of atorvastatin should be consid ...
Topical treatment for cutaneous leishmaniasis Tracy Garnier
... WC1E 7HT UK Email: [email protected] *To whom correspondence should be addressed Current Opinion in Investigational Drugs 2002 3(4): © PharmaPress ISSN 1472-4472 ...
... WC1E 7HT UK Email: [email protected] *To whom correspondence should be addressed Current Opinion in Investigational Drugs 2002 3(4): © PharmaPress ISSN 1472-4472 ...
Chemotherapy extravasation guideline
... steroids may induce ulcers in high doses and their effectiveness is not proven. Alternatively it is suggested that steroids would suppress the local inflammation caused by tissue trauma that occurs during the treatment process. This guideline does not advocate the use of subcutaneous steroids. Topic ...
... steroids may induce ulcers in high doses and their effectiveness is not proven. Alternatively it is suggested that steroids would suppress the local inflammation caused by tissue trauma that occurs during the treatment process. This guideline does not advocate the use of subcutaneous steroids. Topic ...
ELOCON Lotion
... for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the subjects, demonstrated suppressed HPA axis function in 1 subject, using these same cri ...
... for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 8 of the subjects, demonstrated suppressed HPA axis function in 1 subject, using these same cri ...
QA_18_6_AmlodipinevsfelodipineAUG_15_FINAL
... less dependent on patient factors such as age and race compared with other antihypertensive agents such as ACE inhibitors.(6) Current advice from NICE recommends calcium channel blockers as potential first line agents in older patients (over 55 years) or black patients of any age and as potential se ...
... less dependent on patient factors such as age and race compared with other antihypertensive agents such as ACE inhibitors.(6) Current advice from NICE recommends calcium channel blockers as potential first line agents in older patients (over 55 years) or black patients of any age and as potential se ...
Guidelines for the prescribing and administration of `when required
... Once printed, this document could become out of date. Check Ourspace for the latest version. ...
... Once printed, this document could become out of date. Check Ourspace for the latest version. ...
HƯỚNG DẪN VỀ DƯỢC PHẨM INCIVEK
... combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null respon ...
... combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null respon ...
Antidepressants for insomnia
... used long-term for the treatment of insomnia. This was the consensus view of the panel of a 1983 National Institute of Health (NIH 1983) Consensus Conference on the medication treatment of insomnia, which became a guideline for clinical practice in the United States (US). Later the UK Committee on S ...
... used long-term for the treatment of insomnia. This was the consensus view of the panel of a 1983 National Institute of Health (NIH 1983) Consensus Conference on the medication treatment of insomnia, which became a guideline for clinical practice in the United States (US). Later the UK Committee on S ...
Standard operating procedures of the electrochemotherapy
... in tissues. To date, its main application has been the treatment of tumour nodules when the electric pulses are associated with non-permeant drugs having high intrinsic cytotoxicity. The most convenient drug is bleomycin, a currently used anticancer drug, but cytotoxicity of cisplatin is also increa ...
... in tissues. To date, its main application has been the treatment of tumour nodules when the electric pulses are associated with non-permeant drugs having high intrinsic cytotoxicity. The most convenient drug is bleomycin, a currently used anticancer drug, but cytotoxicity of cisplatin is also increa ...
Cost-effectiveness of anticoagulants for suspected
... patients with suspected HIT treated with argatroban, bivalirudin, or fondaparinux as alternative anticoagulants to the discontinued heparin products (Figure 1). This model was designed to calculate cost in US dollars (USD) per adverse event averted. The model was tested in probabilistic sensitivity ...
... patients with suspected HIT treated with argatroban, bivalirudin, or fondaparinux as alternative anticoagulants to the discontinued heparin products (Figure 1). This model was designed to calculate cost in US dollars (USD) per adverse event averted. The model was tested in probabilistic sensitivity ...
Module III
... Clinical trials have established the effectiveness of buprenorphine for the treatment of heroin addiction. Effectiveness of buprenorphine has been compared to: Placebo (Johnson et al. 1995; Ling et al. 1998; Kakko et al. 2003) Methadone (Johnson et al. 1992; Strain et al. 1994a, 1994b; Ling et al. 1 ...
... Clinical trials have established the effectiveness of buprenorphine for the treatment of heroin addiction. Effectiveness of buprenorphine has been compared to: Placebo (Johnson et al. 1995; Ling et al. 1998; Kakko et al. 2003) Methadone (Johnson et al. 1992; Strain et al. 1994a, 1994b; Ling et al. 1 ...